Mountain View, CA (October 23, 2014)– Fenwick is pleased to announce that the firm represented Resolve Therapeutics, LLC in the creation of a partnership that has been recognized as the Licensing & Collaboration Impact Deal of the Year by LMG Life Sciences.
Partners Effie Toshav, Jake Handy, Matthew Rossiter, Michael Solomon and Stefano Quintini represented Resolve in its $250 million partnership with Takeda Pharmaceutical Company to facilitate the development of compounds for the treatment of lupus and other autoimmune diseases.
According to the Lupus Foundation of America, approximately 1.5 million people in the United States and at least 5 million people worldwide have a form of lupus. This chronic autoimmune disease creates antibodies that attack, inflame and damage parts of the body, causing a variety of disabling symptoms.
Under the partnership agreement, Seattle-based Resolve is conducting all development work of the lead compound, RSLV-132, through the completion of the Phase 1b/2a trial. Resolve announced the initiation of a multi-dose, one-month phase 2 clinical study of RSLV-132 in patients with systemic lupus erythematosus (SLE) on July 16, 2014.
Upon the completion of the Phase 1b/2a trial, Takeda has the exclusive option to license RSLV-132 and all other compounds from the Resolve platform, allowing Takeda to take lead responsibility for worldwide development and commercialization of the Resolve products.
About Fenwick & West
Fenwick & West provides comprehensive legal services to groundbreaking technology and life sciences companies at every stage of their lifecycle. We craft innovative, cost-effective and practical solutions for established and emerging companies on issues ranging from venture capital, public offerings, joint ventures, M&A and strategic relationships, to intellectual property, litigation and dispute resolution, taxation, antitrust, and employment and labor law. For more than four decades, Fenwick has helped some of the world's most recognized companies become and remain market leaders.